ALLR

0.78509.25%
UA

Ursula A. Matulonis

Member of Scientific Advisory Board

Dr. Professor Ursula A. Matulonis, MD, serves as Member of Scientific Advisory Board at NextCure, Inc. from October 2021. She is Chief and Director of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She co-leads the ovarian cancer program within the Dana-Farber/Harvard Cancer Center. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer. She has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, and combination trials for ovarian cancer in the United States and internationally. She serves on the Massachusetts Ovarian Cancer Task Force and the Scientific Advisory Board for the Ovarian Cancer Research Foundation and the Clearity Foundation. She co-leads the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA. She is a Member of Scientific Advisory Board at Allarity Therapeutics A/S (formerly known as Oncology Venture A/S).

Positions